We are live on ! Find out more
CYTO icon

Altamira Therapeutics Ltd

Delisted

CYTO was delisted on the 19th of December, 2024.

6 hedge funds and large institutions have $34.5K invested in Altamira Therapeutics Ltd in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.13% less ownership

Funds ownership: 2.74% → 0.61% (-2.1%)

54% less funds holding

Funds holding: 13 → 6 (-7)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

80% less capital inflows, than outflows

Capital inflows: $20K | Capital outflows: $98.9K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 7

Holders
6
Holders Change
-7
Holders Change %
-53.85%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
3
Closed
7
Calls
$49​K
Puts
–
Net Calls
+$49​K
Net Calls Change
+$38​K

CYTO Hedge Fund Activity: Q4 2022 in Review

6 of the 6,245 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q4 2022, worth a combined $34.5K — down 71% from $119K a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of CYTO and 0 opened new positions — a net loss of 7 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, adding an estimated $20K. The largest seller was Virtu Financial, exiting entirely with an estimated $36K sold.

  • 6 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q4 2022, down from 13 in Q3 2022.
  • Funds reported $34.5K of Altamira Therapeutics Ltd stock for Q4 2022, down 71% quarter-over-quarter.
  • 0 funds opened new Altamira Therapeutics Ltd positions in Q4 2022 and 7 closed out, a net change of -7 holders.
  • The largest Altamira Therapeutics Ltd buyer in Q4 2022 was UBS Group, an estimated $20K added.
  • The largest Altamira Therapeutics Ltd seller in Q4 2022 was Virtu Financial, an estimated $36K sold.

Based on aggregated 13F filings for Q4 2022.